Quality matters: immunotherapy and the evolving landscape of advanced cancer care

References

• Alexandrov L, Nik-Zainal S, Wedge D, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415–421.
   Google Scholar
• Aaronson N, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;5:365–376.
   Google Scholar
• Ribas A, Puzanov I, Dummer R, et al. Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16:908–918.
   Google Scholar
• Robert C, Schachter J, Long G, et al. Pembrolizumab versus Ipilimumab in advanced melanoma. N Eng J Med. 2015;372:2521–2532.
   Google Scholar
• Schadendort D, Dummer R, Hauschild A, et al. Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. Eur J Cancer. 2016;67:46–54.
   Google Scholar
• Reck M, Coon C, Taylor F, et al. Evaluation of overall health status in patients with advanced squamous non-small cell lung cancer treated with nivolumab or docetaxel in CheckMate 017. ESMO Asia. 2015;51(supplement 3):S599-S600.
   Google Scholar
• Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non–small-cell lung cancer. N Eng J Med. 2015;373:1637–1639.
   Google Scholar
• Herbst R, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. The Lancet. 2016;387(10027):1540–1550.
   Google Scholar
• Brahmer J, Rodriguez-Abreu D, Robinson A, et al. PL04a.01: health-related quality of life for pembrolizumab vs chemotherapy in advanced NSCLC with PD-L1 TPS ≥50%: data from KEYNOTE-024. Journal of Thoracic Oncology. 2017;12(1):S8–S9.
   Google Scholar
• Zagadailov E, Michael F, Shields A. Patient-reported outcomes are changing the landscape in oncology care: challenges and opportunities for payers. Am Health Drug Benefits. 2013;6(5):264–274.
   Google Scholar
• Lipscomb J, Snyder CF, Gotay CC. Cancer outcomes measurement: through the lens of the Medical Outcomes Trust framework. Qual Life Res. 2007;16:143–164.
   Google Scholar
• Schwartz RH. Costimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapy. Cell. 1992;71(7):1065–1068.
   Google Scholar
• Tan S, Zhang C, Gao G. Seeing is believing: anti-PD-1/PD-L1 monoclonal antibodies in action for checkpoint blockade tumor immunotherapy. Signal Transduction Targeted Therapy. 2016;1:e16029.
   Google Scholar
• Pardoll D. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252–264.
   Google Scholar
• Hodi F, O’Day S, McDermott D, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–723.
   Google Scholar
• Niezgoda H, Pater J. A validation study of the domains of the core EORTC quality of life questionnaire. Qual Life Res. 1993;2:319–325.
   Google Scholar
• Revick D, Eertwegh A, Lorigan P, et al. Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment. Health Qual Life Outcomes. 2012;10:66.
   Google Scholar
• Robert C, Long G, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Eng J Med. 2015;372:320–330.
   Google Scholar
• Tsuchiya A, Ikeda S, Ikegami N, et al. Estimating an EQ-5D population value set: the case of Japan. Health Econ. 2002;11:341–353.
   Google Scholar
• Long G, Atkinson V, Ascierto PA, et al. Effect of nivolumab on health-related quality of life in patients with treatment-naïve advanced melanoma: results from the phase III CheckMate 066 study. Ann of Oncol. 2016;27:1940–1946.
   Google Scholar
• Brahmer J, Horn L, Antonia S, et al. Survival and long-term follow-up of the phase I trial of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC). Journal of Clinical Oncology. 2013;31(supplement 15):8030.
   Google Scholar
• Brahmer J, Reckamp K, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non–small-cell lung cancer. N Eng J Med. 2015;373:123–135.
   Google Scholar
• Horn L, Brahmer J, Reck M, et al. Phase 3, randomized trial (CheckMate 057) of nivolumab vs docetaxel in advanced non-squamous (non-SQ) non-small cell lung cancer (NSCLC): subgroup analyses and patient reported outcomes (PROs). Ann of Oncol. 2015;26(suppl_9):ix125.
   Google Scholar
• Garon E, Rizvi N, Hui R, et al. Pembrolizumab for the treatment of non–small-cell lung cancer. N Eng J Med. 2015;372:2018–2028.
   Google Scholar
• Reck M, Rodriuez-Abreu D, Robinson A, et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. N Eng J Med. 2016;375:1823–1833.
   Google Scholar
• Langer C, Gadgeel S, Borghaei H, et al. Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study. Lancet Oncol. 2016;17(11):1497–1508.
   Google Scholar
• Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389(10066):255–265.
   Google Scholar
• Sharma P, Callahan M, Bono P, et al. Nivolumab monotherapy in recurrent metastatic urothelial carcinoma (CheckMate 032): a multicentre, open-label, two-stage, multi-arm, phase 1/2 trial. Lancet Oncol. 2016;17(11):1590–1598.
   Google Scholar
• Bellmunt J, De Wit R, Vaughn D, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. New Eng J Med. 2017;376:1015–1026.
   Google Scholar
• Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2017;18:312–322.
   Google Scholar
• Vaughn D, Bellmunt J, De Wit R, et al. Health-related quality of life (HRQoL) in the KEYNOTE-045 study of pembrolizumab versus investigator-choice chemotherapy for previously treated advanced urothelial cancer. J Clin Oncol 2017;35:suppl 6s abstract 282.
   Google Scholar
• Motzer R, Escudier B, McDermott D, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Eng J Med. 2015;375:1803–1813.
   Google Scholar
• Cella D, Grunwald V, Nathan P, et al. Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial. Lancet Oncol. 2016;17(7):994–1003.
   Google Scholar
• Ferris R, Blumenschein G, Fayette J, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Eng J Med. 2016;375:1856–1867.
   Google Scholar
• Ferris R, Blumenschein G, Fayette J, et al. Further evaluations of nivolumab (nivo) versus investigator’s choice (IC) chemotherapy for recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CheckMate 141. J Clin Oncol. 2016;34:6009.
   Google Scholar
• Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol. 2016;27(4):559–574.
   Google Scholar
• Lacouture ME, Wolchok JD, Yosipovitch G, et al. Ipilimumab in patients with cancer and the management of dermatologic adverse events. J Am Acad Dermatol. 2014;71:161.
   Google Scholar
• Hodi FS, Mihm MC, Soiffer RJ, et al. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc Natl Acad Sci USA. 2003;100:4712.
   Google Scholar
• Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32:1020.
   Google Scholar
• Postow M, Wolchok J Toxicities associated with checkpoint inhibitor immunotherapy. [updated 2017 Mar]. http://www.uptodate.com.ckmproxy.mc.vanderbilt.edu/contents/toxicities-associated-with-checkpoint-inhibitorimmunotherapy?source=search_result&search=checkpoint%20inhibitor%20toxicity&selectedTitle=1~79#H645515
   Google Scholar
• Younes A, Santoro A, Shipp M, et al. Nivolumab for classical Hodgkin’s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17(9):1283–1294.
   Google Scholar
• Calvert M, Blazeby J, Altman D, et al. Reporting of patient-reported outcomes in randomized trials the CONSORT PRO extension. JAMA. 2013;309(8):814–822.
   Google Scholar
• Revicki D, Feeny D, Hunt T, et al. Analyzing oncology clinical trial data using the Q-TWiST method: clinical importance and sources for health state preference data. Qual Life Res. 2006;15(3):411–423.
   Google Scholar
• Beaumont J, Salsman J, Diaz J, et al. Quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of pazopanib versus sunitinib in patients with renal cell carcinoma. Cancer. 2016;122(7):1108–1115.
   Google Scholar
• Le D, Uram J, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Eng J Med. 2015;372:2509–2520.
   Google Scholar
• Gangadhar T, Hamid O, Smith DC, et al. Epacadostat plus pembrolizumab in patients with advanced melanoma and select solid tumors: updated phase 1 results from ECHO 202/KEYNOTE-037. Ann Oncol. 2016;27(suppl_6):1110PD.
   Google Scholar
• Infante J, Hansen A, Pishvaian M, et al. A phase Ib dose escalation study of the OX40 agonist MOXR0916 and the PD-L1 inhibitor atezolizumab in patients with advanced solid tumors. J Clin Oncol. 2016;34:101–101.
   Google Scholar
• Lee Y, Auh S, Wang Y, et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment. Blood. 2009;114:589–595.
   Google Scholar
• Postow M, Callahan M, Barker C, et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Eng J Med. 2012;366:925–931.
   Google Scholar